Status: Recruiting
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
Participants needed: 250
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Vor BiopharmaUpdated: Jun 4, 2026Locations: 26
Eligibility criteria
Male or female aged 18 to 75 years of age (both inclusive) at screening [+3]
Participants who have a systemic autoimmune disease other than Primary Sjogren's... [+4]